WASHINGTON — President Trump’s much-ballyhooed drug pricing address Friday contained little of the fiery rhetoric that so often accompanies his campaign speeches and off-script asides. And the policy document that was supposed to detail his vague remarks offered more flash than specifics.

It’s unclear how the bevvy of proposals would work independently or together to actually save money for patients. The blueprint offers few specific details about how any of these ideas would be implemented, and barely commits the government to doing anything, often saying that the Department of Health and Human Services “may” take certain actions.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Guys, this anti-Trump slant and lack of diverse thinking is very bad. It affects the way you interpret information, and more importantly, it ultimately produces a different, less-accurate analysis; as well as less accurate reporting.

    You probably understand that when Alex talks about eliminating rebates, he’s talking about his intention to completely rework the list price. I mean, he did explicitly say that he’s against a system that drives up the list price and he intends to completely change the system, detailing the actual strategies he’s considering to accomplish this. And, yet look at this quote from the article:

    “…following Trump’s Friday speech, Azar animatedly elaborated. “We are calling into question today the entire structure of using rebates as the method of negotiating discounts in the pharmacy channel,” Azar said. It’s unclear what impact this would have on drug prices for patients. It’s also unclear how the government could both eliminate rebates and follow through on an idea included in the president’s budget, where rebates would be passed to consumers.”

    This doesn’t convey the actual reality to readers. It may not be clear to you, but to anyone who’s not burdened by dislike, contempt, or political bias associated with Trump’s administration, it’s actually clear and simple to grasp.

  • Of course Donnies speech was sparse on details. That means he has no plan, just a bunch of hot air. He never does anything that does not benefit himself.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy